



Staphylococci Antimicrobial Tolerance, Persistent Infection and Antimicrobial Strategies

Guest Editors:

Prof. Dr. Lei He

Department of Laboratory
Medicine, Renji Hospital, School
of Medicine, Shanghai Jiaotong
University, Shanghai 200127,
China

Prof. Dr. Xiancai Rao

Department of Microbiology,
College of Basic Medical
Sciences, Army Medical
University, 30 Gaotanyan Street,
Shapingba District, Chongqing
400038, China

Prof. Dr. Yan Chen

Department of Infectious
Diseases, Sir Run Run Shaw
Hospital, Zhejiang University
School of Medicine, Zhejiang
310016, China

Deadline for manuscript
submissions:

closed (30 October 2023)

Message from the Guest Editors

Dear Colleagues,

Staphylococci are pathogens causing a vast array of infections. These organisms can infect virtually any tissue of the body. They were designated as a “persistent pathogen” due to their unusual recalcitrance towards antibiotic treatment, which to date has remained a major clinical challenge. Current antibiotics present a reduced capacity to eradicate staphylococci without surgical support. The application of “omics” technology to investigate staphylococcal physiological change mechanisms during infections helps us to understand the triggers of increased antibiotic survival. Due to a growing awareness of increased antibiotic survival, a great deal of research has turned its focus to new ways of treating and eradicating tolerant staphylococci. However, more studies are needed to better understand the dynamics, mechanisms and relevance of tolerant staphylococci at the site of infection. This Special Issue seeks manuscript submissions that further our understanding of advanced Staphylococci antimicrobial tolerance, persistent infection and antimicrobial strategies.

Prof. Dr. Lei He

Prof. Dr. Xiancai Rao

Prof. Dr. Yan Chen





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)